AVACTA GROUP PLC — AGM Information 2013

Jan 25, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4190W

Avacta Group PLC

25 January 2013

Press Release	25 January 2013

Avacta Group plc

("Avacta" or "the Group")

Result of AGM

Avacta Group plc (AIM:AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, announces that at its Annual General Meeting held today, all resolutions put to shareholders were duly passed.

- Ends -

For further information please contact:

Avacta Group plc
Alastair Smith, Chief Executive Officer	Tel:  +44 (0) 844 414 0452
Tim Sykes, Chief Financial Officer	www.avacta.com
Broker and Nominated Adviser Panmure Gordon (UK) Limited	Tel: +44 (0) 20 7886 2500
Fred Walsh / Andrew Burnett / Grishma Patel Charles Leigh-Pemberton (Corporate broking)

Media Enquiries - Abchurch Communications
Sarah Hollins / Adam Michael / Harriet Rae	Tel: +44 (0) 20 7398 7718
harriet.rae@abchurch-group.com	www.abchurch-group.com

Notes to Editors:

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.

Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.

The cost of healthcare is driven by many factors. New drugs are expensive to develop, most that start the development process never reach the patient, and those that do are often very costly to prescribe. Inadequate, incorrect and slow diagnosis of disease cause delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.

Avacta is dedicated to reducing global healthcare costs. It does this through developing and providing innovative and practical tools to help drug developers get their products to market faster and more reliably, and to provide clinicians with rapid and powerful diagnostics to improve patient treatment.

Avacta joined AIM in August 2006 and is based in Wetherby, UK.

For further information visit www.avacta.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGEALFSADFDEFF